This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.11% and 1.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is the Options Market Predicting a Spike in The Pennant Group (PNTG) Stock?
by Zacks Equity Research
Investors need to pay close attention to The Pennant Group (PNTG) stock based on the movements in the options market lately.
Why The Pennant Group, Inc. (PNTG) Might be Well Poised for a Surge
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does The Pennant Group, Inc. (PNTG) Have the Potential to Rally 29% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 29.4% upside potential for The Pennant Group, Inc. (PNTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Pennant Group, Inc. (PNTG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 37.50% and 4.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of -10.26% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Tops Q1 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.32% and 0.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) to Spin Off Home Health & Hospice Unit
by Zacks Equity Research
Encompass Health (EHC) expects the Enhabit Home Health & Hospice spinoff to be completed in first-half 2022.
The Pennant Group, Inc. (PNTG) Matches Q3 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 0.00% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Pennant Group, Inc. (PNTG) Misses Q2 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -10.53% and 2.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate The Pennant Group, Inc. (PNTG) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 23rd
by Zacks Equity Research
PNTG, GHLD, EXPI, ACR and AG have been added to the Zacks Rank #5 (Strong Sell) List on June 23, 2021.
The Pennant Group (PNTG) is in Overbought Territory: What's Next?
by Zacks Equity Research
The Pennant Group (PNTG) has moved higher as of late, but there could definitely be trouble on the horizon for this company
The Pennant Group, Inc. (PNTG) Q1 Earnings Miss Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -38.89% and 1.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Can The Pennant Group, Inc. (PNTG) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Top Outpatient and Home Healthcare Stocks to Watch Out For
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, USPH and PNTG are well positioned to gain from the prospects.